Aptazapine

Aptazapine
Clinical data
ATC code	none;
Identifiers
	IUPAC name 2-methyl-1,3,4,14b-tetrahydro-2H,10H-pyrazino[1,2-a]pyrrolo[2,1-c][1,4]benzodiazepine;
CAS Number	71576-40-4 ;
PubChem CID	51355;
ChemSpider	46513 ;
UNII	240J927J1R;
KEGG	D02972 ;
ChEMBL	ChEMBL336712 ;
CompTox Dashboard (EPA)	DTXSID40868020 ;
Chemical and physical data
Formula	C16H19N3
Molar mass	253.349 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c42c(N3C(c1cccn1C2)CN(CC3)C)cccc4;
	InChI InChI=1S/C16H19N3/c1-17-9-10-19-14-6-3-2-5-13(14)11-18-8-4-7-15(18)16(19)12-17/h2-8,16H,9-12H2,1H3 ; Key:MNHDDERDSNZCCK-UHFFFAOYSA-N ;
	(what is this?) (verify)

Aptazapine (developmental code name CGS-7525A) is a tetracyclic antidepressant (TeCA) that was assayed in clinical trials for the treatment of depression in the 1980s but was never marketed. It is a potent α₂-adrenergic receptor antagonist with about 10 times the strength of the related compound mianserin and has also been shown to act as a 5-HT₂ receptor antagonist and H₁ receptor inverse agonist, while having no significant effects on the reuptake of serotonin or norepinephrine. Based on its pharmacological profile, aptazapine may be classified as a noradrenergic and specific serotonergic antidepressant (NaSSA).